Regarding influenza vaccination, a prospective study of BCMA and CD19 CAR-T-cell therapy recipients vaccinated with quadrivalent influenza at a median of 20 months postinfusion, demonstrated that 31–40% had robust (4-fold) increase in at least one vaccine target [120▪]. Here, CD19 is linked to influenza.